Severity
Low
FDA Drug recall · Reported April 30, 2014
Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.
GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline recalled Nicorette Lozenge and NicoDerm CQ, nicotine polacrilex system. 189 2mg Mint Flavored Loze… — a low-severity action.
Nicorette Lozenge and NicoDerm CQ, nicotine polacrilex system. 189 2mg Mint Flavored Loze… was recalled by GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline in April 30, 2014. Reason: Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.. Check the official notice for the remedy. Verify recall #D-1247-2014 with the FDA Drug before acting.
The recall
GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline issued this low-severity FDA Drug recall — Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent..
Sourced from official FDA Drug enforcement records. Verify recall #D-1247-2014 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1247-2014) was formally reported on April 30, 2014, with the manufacturer initiating the action on February 20, 2014. It is classified under Low severity (Class III), with a current status of Terminated. GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline is listed as the recalling firm, operating out of Aiken, SC. Federal records list the affected scope as 150 cases.
The documented reason for this recall is: Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent. Distribution data in the federal record shows the product reached: U.S. Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug — clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category — 14,048 drugs & medications recalls on record
Of 100,165 recalls in the database, 23,668 are high severity, 72,097 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger — we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
150 cases
Related Recalls
6
5 from same agency
Nicorette Lozenge and NicoDerm CQ, nicotine polacrilex system. 189 2mg Mint Flavored Lozenges + 21 31 mg Patches. OTC Only. GlaxoSmithKlein, 1000 GSK Drive, Moon Township, PA 15108. UPC: 0-03-0766-1480-30-2.
Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-1247-2014 |
| Date reported | April 30, 2014 |
| Date initiated | February 20, 2014 |
| Recalling firm | GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline |
| Firm location | Aiken, SC |
| Affected scope | 150 cases |
| Distribution | U.S. Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Keep tracking product safety across the federal recall archive.
Recall Checker
Search the full archive by product name, brand, or recall number across every agency.
Check a product →
FDA Drug recalls
Every recall issued by FDA Drug, newest first.
Browse the feed →
RecallRadar
Live feed of the latest recalls across the FDA, CPSC and NHTSA — filter by agency and severity.
View the live feed →
Rankings
The largest recalls by units affected and the most-recalled product categories.
See the rankings →
Browse by category
Find recalls by product type to spot recurring defect patterns.
All categories →
What to do next
A step-by-step guide to refunds, repairs, and returns after a recall.
Read the guide →
Other recalls in the same product category — useful for spotting patterns across the same defect class or manufacturer.
AVEVA Drug Delivery Systems, Inc. · 2026-06-03
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Compare this recall with Nicotine Transdermal System Patch, 14 mg, 14 patches per bo… →
Source: FDA, CPSC, and NHTSA federal recall databases. This recall: FDA Drug, reported April 30, 2014.
Recall information is sourced from official federal agency databases. Always verify recall details with the issuing agency for the most current status. This information is for research and awareness purposes only.
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records — no number is typed in by an editor. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of June 2026.